They Just Don't Get...
Health Care: Drugs
EntreMed Inc. (ENMD: NASDAQ)
$2.03 0.07 | 3.57%
06/04/12 - 03:59 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -4.56M | -8.10M | -8.22M | -23.86M |
| Operating Gains/Losses | -9.50K | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 817.70K | 536.46K | 630.58K | 128.24K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -897.68K | -617.60K | -1.53M | -1.05M |
| (Decrease) Increase In Other Current Liabilities | -344.58K | -149.84K | -1.86M | 908.51K |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | -119.60K |
| Other Non-Cash Items | 609.72K | 3.35M | 524.17K | 3.46M |
| Net Cash From Continuing Operations | -4.27M | -4.96M | -10.21M | -20.71M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -4.27M | -4.96M | -10.21M | -20.71M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 26.81K | 0.00 | 15.50M | 62.52M |
| Purchases of Property, Plant & Equipment | -6.00K | -3.60K | -2.89K | -134.06K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | -7.99M | -51.56M |
| Other Cash from Investing Activities | 56.50K | 2.00K | -4.44K | 4.44K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 77.31K | -1.60K | 7.50M | 10.84M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 1.31M | 0.00 | 0.00 | 0.00 |
| Repayment of Long-Term Debt | -757.47K | -8.55M | -7.71M | -2.98M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | -76.96K |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -164.96K | 12.09M | -10.32K | 0.00 |
| Net Cash From Financing Activities | 389.63K | 3.54M | -7.72M | -3.06M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -3.81M | -1.43M | -10.43M | -12.93M |
Portfolios with ENMD
- Portfolio NameUser Type
- Contributor6 Drug Stocks Unworthy of B...
- UserBeaver
- Contributor10 Stocks Under $5 Outperfo...
- ContributorStocks Under $5 at Risk of ...
- UserDorkingLad Portfolio 1
- Usersmallbiz
- Usersteves #1
- UserThe Investment Psychologist...
- Userdrweik Portfolio 1
- UserJake's Portfolio 1
Latest ENMD Headlines from TheStreet
- 6 Drug Stocks Unworthy of Biotech Bull Market 02.07.12 | 12:02 pm
- 5 Stocks Under $10 Poised for Big Upside 02.03.12 | 02:02 pm
- 10 Stocks Under $5 Outperforming in 2012 01.31.12 | 05:01 am
- Stocks Under $5 at Risk of Bankruptcy 06.08.11 | 06:06 am
- Biotech Sector Weekly Rewind 11.20.10 | 08:11 am
- Stock Offerings: Two Harbors 04.19.10 | 10:04 am
- Sprint Nextel, Palm: Early Volume Plays 04.19.10 | 07:04 am
- ThermoGenesis, Power-One: Early Volume Plays 02.05.10 | 07:02 am
- Netlist, EntreMed: Midday Volume Plays 12.14.09 | 02:12 pm
- ExpressJet, Entremed: Midday Volume Plays 11.16.09 | 02:11 pm
Press Releases for ENMD
- EntreMed Appoints Interim CEO - PR Newswire 04.03.12 | 07:04 am
- EntreMed Initiates Plans For China Office - PR Newswire 03.05.12 | 02:03 pm
- EntreMed Completes Strategic Financing - PR Newswire 02.06.12 | 07:02 am
- Biotech Leaders Wei-Wu He, Ph.D And Tak W. Mak, Ph.D Join EntreMed's Board Of Directors - PR Newswire 02.06.12 | 07:02 am
- EntreMed's ENMD-2076 Demonstrates Promising Activity In A Phase 2 Study In Platinum-Resistant Ovarian Cancer Patients - PR Newswire 10.03.11 | 07:10 am
- EntreMed Enters Into $7.5 Million Equity Facility And Initiates $1.1 Million Drawdown - PR Newswire 06.28.11 | 05:06 pm
- Selected Value Therapeutics Exercises Right To Develop And Commercialize Enmd-2076 In China - PR Newswire 06.07.11 | 11:06 am
- EntreMed's ENMD-2076 Demonstrates Clinical Activity In Recurrent, Platinum-Resistant Ovarian Cancer Patients - PR Newswire 06.03.11 | 03:06 pm
- EntreMed Reports Fourth Quarter And Year-End 2009 Financial Results - PR Newswire 03.29.10 | 04:03 pm
Partner Headlines for ENMD
- China Biotech In Review: GSK Explores All Paths To Increase China Presence - Seeking Alpha 03.11.12 | 07:03 am
- China Biotech Week in Review: Shanghai Pharma Plans $1.2 Billion IPO - Seeking Alpha 09.12.10 | 09:09 am
- Big Pharma Looks to Biotech for Innovation - Seeking Alpha 09.12.10 | 08:09 am
- EntreMed Widens Loss in 2Q, Clinical Trials for Ovarian Cancer Progress - Fox Business 08.16.10 | 12:08 pm
